Chronic Obstructive Pulmonary Disease Is Associated With Decreased Quality of Life in Bronchiectasis Patients: Findings From the KMBARC Registry

Sang Hyuk Kim1, Changhwan Kim2, Ina Jeong3, Seung Jun Lee4, Tae Hyung Kim5, Chang Youl Lee6, Yeon-Mok Oh7, Hyun Lee*5 and Youlim Kim*6† on behalf of the KMBARC

Most studies have evaluated the impact of non-cystic fibrosis bronchiectasis (hereafter referred to as bronchiectasis) on quality of life (QoL) in patients with chronic obstructive pulmonary disease (COPD) using COPD cohorts. Accordingly, the impact of COPD on QoL in patients with bronchiectasis is not well-elucidated. We used the Korean MulticenterBronchiectasis Audit and Research Collaboration (KMBARC) registry between August 2018 and December 2019, a prospective observational cohort that enrolled patients with bronchiectasis in Korea. We evaluated co-occurrence exposure to COPD in bronchiectasis patients, and the primary outcome was QoL according to the Bronchiectasis Health Questionnaire (BHQ). We also investigated factors associated with decreased QoL, defined as the lowest quartile of the total BHQ score. Of 598 patients with bronchiectasis, 372 (62.2%) had COPD. Bronchiectasis patients with COPD had a significantly lower total BHQ score compared with those without COPD [median = 63.1 (interquartile range: 54.8–68.6) vs. 64.8 (57.4–70.8), p = 0.020].Multivariable analysis revealed that dyspnea [adjusted odds ratio (aOR) = 3.21, 95% confidence interval (CI) = 1.21–8.60], depression (aOR = 1.28, 95% CI = 1.16–1.44), and fatigue (aOR = 1.05, 95% CI = 1.01–1.09) were significantly associated with decreased QoL in bronchiectasis patients with COPD. In conclusion, bronchiectasis patients with COPD had significantly decreased QoL than patients without COPD. In bronchiectasis patients with COPD, dyspnea, depression, and fatigue were associated with decreased QoL.

Keywords: chronic obstructive pulmonary disease, bronchiectasis, quality of life, bronchiectasis health questionnaire, COPD overlap
INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a common pulmonary comorbidity of non-cystic fibrosis bronchiectasis (hereafter referred to as bronchiectasis), ranging from 15 to 38% prevalence in bronchiectasis patients (1–5). These two conditions facilitate each other's disease progression (6), resulting in a worse prognosis, including mortality.

However, except for studies evaluating COPD prevalence in patients with bronchiectasis, most studies have focused on the impact of bronchiectasis in COPD patients (7–10). These studies showed that the coexistence of bronchiectasis and COPD was associated with a larger number of symptoms, worse lung function, greater disease severity, and more frequent exacerbations (7–10). Accordingly, COPD patients with bronchiectasis have worse quality of life (QoL) than patients with COPD only (11, 12). Because these studies used COPD cohorts, the impact of bronchiectasis on QoL in COPD patients could have been elucidated better. However, little is known about this association within a bronchiectasis cohort because few studies have evaluated bronchiectasis cohorts; thus, urgent evaluation of this issue is necessary.

The Korean Multicenter Bronchiectasis Audit and Research Collaboration (KMBARC) is a prospective, observational study of bronchiectasis in Korea (13, 14). The KMBARC uses the Korean version of the Bronchiectasis Health Questionnaire (BHQ) for QoL measurement (15), which has the advantage of simplicity over other QoL measurements for bronchiectasis. Accordingly, we hypothesized that the BHQ QoL would be worse in bronchiectasis patients with COPD than in those without COPD. We further aimed to evaluate which factors are associated with impaired QoL in bronchiectasis patients with COPD.

MATERIALS AND METHODS

Study Population

The KMBARC is a prospective, non-interventional observational cohort study conducted since August 2018 to uncover the natural course of bronchiectasis in Korea. We used baseline data from 598 participants enrolled between August 2018 and December 2019. The KMBARC inclusion criteria were adult patients (aged ≥ 18 years) with stable bronchiectasis. In this study, bronchiectasis was defined when bronchodilation was found in computed tomography of the lung, which included one or more of the followings: (1) bronchoarterial ratio > 1 (internal airway lumen vs. adjacent pulmonary artery), (2) lack of tapering, or (3) airway visibility within 1 cm of costal pleural surface or touching mediastinal pleura (16). The exclusion criteria were: (1) cystic fibrosis bronchiectasis, (2) interstitial lung-disease-related traction bronchiectasis, (3) active treatment for pneumonia, pulmonary tuberculosis (TB), or non-tuberculous mycobacterial infection, (4) lack of informed consent, and (5) pregnancy. Detailed information on the KMBARC protocol was provided in a previous study (13).

The study protocol was approved by the institutional review board of each institution that participated in the KMBARC, including Hallym University Chuncheon Sacred Heart Hospital (IRB number: 2018-07-006). All participants provided written informed consent.

Exposure

The exposure state for this study was the coexistence of COPD with bronchiectasis. COPD was defined as physician-diagnosed COPD, which includes (1) COPD diagnosis by an attending physician in the institution where the patient was enrolled and (2) Patient-reported physician-diagnosed COPD in another institution.

Outcomes

The primary outcome was QoL as measured by BHQ (17). The secondary outcome was factors associated with decreased QoL, defined as the lowest quartile of the total BHQ score.

Covariates

Body mass index (BMI) was calculated by dividing weight by the square of height (kg/m²). Dyspnea was evaluated according to the modified Medical Round Council (mMRC) scale (18). Purulent sputum production was assessed using a sputum color chart (19). Acute exacerbation was defined according to a consensus definition for bronchiectasis (20). Regarding acute exacerbations, we evaluated exacerbation history in the previous year at the time of enrollment. Bronchiectasis severity was assessed by the bronchiectasis severity index (BSI) (21) and Faced score (22). Pseudomonas aeruginosa was isolated from spontaneously obtained sputum, induced sputum samples, or bronchoalveolar lavage. Korean versions of the Patient Health Questionnaire 9 (PHQ-9) and the Fatigue Severity Score (FSS) were used to assess depression and fatigue, respectively (23–26). Modified Reiff score was calculated as previously reported (27). Comorbidities were defined as patient-reported previous physician diagnoses. Spirometry was performed as recommended by the American Thoracic Society and the European Respiratory Society (28). After obtaining absolute values for FEV₁ and FVC, the percentages of predicted values (% predicted) for FEV₁ and FVC were calculated following recommendations for Korean populations (29). Medication data were based on self-reported use.

Statistical Analyses

We presented data as medians with interquartile ranges (IQRs) for continuous variables and numbers with percentages for categorical variables. The p-values were calculated using the Wilcoxon rank-sum test for continuous variables and Pearson’s chi-square test or Fisher’s exact test for categorical variables, as appropriate. We performed univariable and multivariable logistic regression analyses to identify factors associated with decreased QoL in bronchiectasis patients with COPD. Factors included in the multivariable logistic regression model were demographics (age, sex, and smoking history), clinically important variables (acute exacerbation), and factors significantly different (p < 0.05) between the bronchiectasis patients with and without COPD (BMI, mMRC, PHQ-9, FSS, FEV₁ % predicted, asthma, modified Reiff score). As each component of BSI or FACED was included in the model, these variables were not included in the
multivariable models. In addition, due to the high collinearity between pulmonary function parameters, only FEV$_1$ % predicted was adjusted. A two-sided $p$-value $< 0.05$ was considered significant. All analyses were conducted using R version 4.0.3 (R Core Team 2020; R Foundation for Statistical Computing, Vienna, Austria).

**TABLE 1 | Clinical characteristics of the study population according to COPD status.**

|                          | Without COPD ($n = 372$) | With COPD ($n = 226$) | $p$-value |
|--------------------------|--------------------------|-----------------------|-----------|
| Age, years               | 65 (60–71)               | 67 (60–72)            | 0.025     |
| Male, n (%)              | 130 (34.9)               | 134 (59.3)            | <0.001    |
| BMI, kg/m$^2$ ($n = 562$) | 23 (21–25)               | 23 (21–26)            | 0.283     |
| Current or ex-smoker, n (%) | 99 (26.6)               | 112 (46.6)            | <0.001    |
| **Symptoms**             |                          |                       |           |
| mMRC $\geq 2$, n (%)     | 58 (15.6)                | 72 (31.9)             | <0.001    |
| Purulent sputum production ($n = 583$) | 125 (34.2) | 45 (20.7) | <0.001    |
| **Disease severity**     |                          |                       |           |
| Acute exacerbation, n (%) | 189 (50.8)              | 133 (58.8)            | 0.067     |
| Severity index ($n = 582$) | 5 (4–8)          | 7 (5–11)              | <0.001    |
| BSI                      | 3 (1–9)                 | 3 (1–9)               | 0.909     |
| FSS                      | 20 (12–34)              | 20 (12–34)            | 0.990     |
| Number of involved lobes | 3 (2–4)                 | 4 (2–6)               | <0.001    |
| Cystic bronchiectasis in any lobes | 149 (40.9) | 122 (66.0) | 0.001     |
| Modified Reiff score ($n = 569$) | 4 (3–7.5)     | 6 (3–10)              | <0.001    |
| **Comorbidities**        |                          |                       |           |
| Asthma, n (%)            | 69 (18.5)               | 65 (28.8)             | 0.005     |
| Cardiovascular disease, n (%) | 92 (24.7) | 86 (38.1) | <0.001    |
| Diabetes mellitus, n (%) ($n = 597$) | 48 (12.9) | 25 (11.1) | 0.604     |
| Rhinosinusitis, n (%)    | 33 (8.9)                | 20 (8.8)              | 1.000     |
| Neoplastic disease, n (%) ($n = 594$) | 31 (8.4) | 23 (10.2) | 0.547     |
| Tuberculosis, n (%) ($n = 597$) | 102 (27.4) | 96 (42.7) | <0.001    |
| **Pre-bronchodilator spirometry results** |                     |                       |           |
| FVC (L)                  | 2.5 (2.0–3.1)           | 2.4 (1.9–3.0)         | 0.104     |
| FVC (%-predicted)        | 75.7 (66.7–86.7)        | 67.9 (55.8–79.0)      | <0.001    |
| FEV$_1$ (L)              | 1.8 (1.4–2.1)           | 1.4 (1.0–1.8)         | <0.001    |
| FEV$_1$/FVC (%)          | 71.2 (57.3–82.4)        | 53.2 (42.3–64.2)      | <0.001    |
| **Medication**           |                          |                       |           |
| Inhaler ($n = 595$)      |                          |                       |           |
| LABA or LAMA, n (%)      | 17 (4.6)                | 23 (10.3)             | 0.012     |
| ICS/LABA*, n (%)         | 36 (9.7)                | 20 (8.9)              | 0.866     |
| LABA/LAMA*, n (%)        | 49 (13.2)               | 107 (47.8)            | <0.001    |
| ICS/LABA/LAMA, n (%)     | 16 (4.3)                | 39 (17.4)             | <0.001    |
| Oral drug ($n = 596$)    |                          |                       |           |
| Statin, n (%)            | 21 (5.7)                | 16 (7.1)              | 0.592     |
| ACE inhibitor, n (%)     | 8 (2.2)                 | 1 (0.4)               | 0.189     |
| Proton pump inhibitor, n (%) | 29 (7.8) | 19 (8.4) | 0.906     |

Data are expressed as medians (interquartile ranges) for continuous variables and numbers (percentages) for categorical variables.

*Seven patients switched from one inhaler to the other.

COPD, chronic obstructive pulmonary disease; BMI, body mass index; mMRC, modified Medical Research Council; FEV$_1$, forced expiratory volume in 1 second; FVC, forced vital capacity; BSI, bronchiectasis severity index; PHQ-9, Patient Health Questionnaire 9; FSS, Fatigue Severity Score; LABA, long-acting $\beta_2$ agonist; LAMA, long-acting muscarine antagonist; ICS, inhaled corticosteroid; ACE, angiotensin-converting enzyme.
RESULTS

Baseline Characteristics
Of 598 bronchiectasis patients, 226 (37.8%) had COPD (Table 1). Compared with patients without COPD, bronchiectasis patients with COPD were older [median 67 years (IQR, 60–72 years) vs. median 65 years (IQR, 60–71 years), \( p = 0.025 \)], more frequently male (59.3 vs. 34.9%, \( p < 0.001 \)), and more likely to be current or ex-smokers (49.6 vs. 26.6%, \( p < 0.001 \)). Regarding symptoms, compared with patients without COPD, while dyspnea (mMRC \( \geq 2 \)) (31.9 vs. 15.6%, \( p < 0.001 \)) was more common, purulent sputum production (20.7 vs. 34.2%, \( p < 0.001 \)) was less frequent in patients with COPD. Regarding disease severity, bronchiectasis patients with COPD had higher BSI [median 7 (IQR, 5–11) vs. median 5 (IQR, 4–8), \( p < 0.001 \)] and FACED [median 3 (IQR, 1–4) vs. median 1 (IQR, 0–3), \( p < 0.001 \)] than patients without COPD. Additionally, Pseudomonas aeruginosa was more commonly isolated from bronchiectasis patients with COPD than patients without COPD (14.6 vs. 8.9%, \( p = 0.042 \)). However, there was no intergroup difference in acute exacerbation. Patients with COPD had a higher number of involved lobes than those without COPD [median 4 (IQR, 2–5) vs. median 3 (IQR, 2–4), \( p < 0.001 \)]. In addition, cystic bronchiectasis was more frequently found in patients with COPD than those without COPD (56 vs. 40.9%, \( p = 0.001 \)). Regarding comorbidities, asthma (28.8 vs. 18.5%, \( p = 0.005 \)), cardiovascular disease (38.1 vs. 24.7%, \( p < 0.001 \)), and tuberculosis (42.7 vs. 27.4%, \( p < 0.001 \)) were more common in bronchiectasis patients with COPD than in patients without bronchiectasis. Bronchiectasis patients with COPD showed lower pulmonary function in terms of FVC (% predicted), FEV\(_1\) (L), FEV\(_1\) (% predicted), and FEV\(_1\)/FVC than those without COPD (\( p < 0.001 \) for all). Bronchiectasis patients with COPD were more frequently prescribed a long-acting muscarinic antagonist (LAMA) or a long-acting \( \beta_2 \) agonist (LABA) (\( p = 0.12 \)), LABA/LAMA (\( p < 0.001 \)), or an inhaled corticosteroid (ICS)/LABA/LAMA (\( p < 0.001 \)) than were patients without COPD. However, there were no differences in use of ICS/LABA, angiotensin-converting enzyme inhibitors (\( p = 0.189 \)), or proton pump inhibitors (\( p = 0.906 \) between the two groups.

Comparison of QoL Between Bronchiectasis Patients With and Without COPD

Figure 1 depicts the comparison of the total BHQ score according to the presence of COPD with bronchiectasis. Bronchiectasis patients with COPD had significantly lower total BHQ scores than patients without COPD [median 63.1 (IQR, 54.8–68.6) vs. median 64.8 (IQR, 57.4–70.8), \( p = 0.020 \)].

Comparison of Characteristics of Bronchiectasis Patients With COPD According to QoL
As shown in Table 2, there were no significant differences in age (\( p = 0.688 \)), sex (\( p = 0.530 \)), smoking history (\( p = 0.425 \)), purulent sputum production (\( p = 0.657 \)), acute exacerbation (\( p = 0.209 \)), the isolation of Pseudomonas aeruginosa (\( p = 0.238 \)), comorbidities, and medications between the bronchiectasis patients with COPD showing decreased QoL and those not. However, the proportion of patients with mMRC \( \geq 2 \) was significantly higher in patients with decreased QoL than in those without decreased QoL (63.1 vs. 18.9%, \( p < 0.001 \)). BMI [median 21.7 kg/m\(^2\) (IQR, 20.1–24.6 kg/m\(^2\)) vs. median 23.6 kg/m\(^2\) (IQR, 21.0–26.0 kg/m\(^2\)), \( p = 0.007 \)] and pulmonary function, including FVC % predicted [median 62.3 % (IQR, 50.3–75.8%) vs. median 69.7% (IQR, 59.0–79.2%), \( p = 0.003 \)] and FEV\(_1\) % predicted [median 46.9% (IQR, 35.1–59.6%) vs. median 60.3% (IQR, 51.9–65.7%), \( p = 0.002 \)] were significantly lower in patients with decreased QoL compared to those without decreased QoL. In contrast, BSI [median 8.5 (IQR, 6–14) vs. median 6 (IQR, 5–9), \( p < 0.001 \)], FACED [median 37 (IQR, 28–51) vs. median 15 (IQR, 0.001)], and BSI scores. Dots outside of boxplots indicate outliers. The \( p \)-value was calculated using the Wilcoxon rank-sum test. COPD, chronic obstructive pulmonary disease; BHQ, bronchiectasis health questionnaires.
| TABLE 2 | Baseline characteristics of bronchiectasis patients with COPD according to QoL. |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                 | Without decreased QoL (N = 159) | With decreased QoL* (N = 65) | p-value |
| Age, years      | 66 (61–72)       | 68 (60–72)       | 0.688 |
| Male, n (%)     | 97 (61.0)        | 36 (55.4)        | 0.530 |
| BMI, kg/m² (n = 221) | 23.6 (21.0–26.0) | 21.7 (20.1–24.6) | 0.007 |
| Current or ex-smoker, n (%) | 82 (51.6)  | 29 (44.6)  | 0.425 |
| Symptoms        |                 |                 |       |
| mMRC ≥ 2, n (%) | 30 (18.9)        | 41 (63.1)        | <0.001 |
| Purulent sputum production (n = 215) | 33 (21.6)  | 11 (17.7)  | 0.657 |
| Disease severity|                 |                 |       |
| Acute exacerbation, n (%) | 89 (56.0) | 43 (66.2) | 0.209 |
| Severity index (n = 216) | 6 (5–9) | 8.5 (6–14) | <0.001 |
| BSI             | 15 (11–23)       | 37 (28–51)       | <0.001 |
| FACED           | 21 (13.2)        | 12 (18.5)        | 0.238 |
| Isolation of Pseudomonas aeruginosa, n (%) | 21 (13.2)  | 12 (18.5)  | 0.238 |
| Health status   |                 |                 |       |
| PHQ-9           | 2 (1–4)          | 11 (7–17)        | <0.001 |
| FFS (n = 223)   | 15 (11–23)       | 37 (28–51)       | <0.001 |
| Radiologic findings (n = 216) |                 |                 |       |
| Cystic bronchiectasis in any lobes | 83 (53.9) | 39 (62.9) | 0.291 |
| Number of involved lobes | 3 (2–5) | 4 (3–5) | 0.039 |
| Modified Reiff score (n = 212) | 6 (3–9) | 8 (5–12) | 0.030 |
| Comorbidities   |                 |                 |       |
| Asthma, n (%)   | 42 (26.4)        | 23 (35.4)        | 0.238 |
| Cardiovascular disease, n (%) | 60 (37.7) | 26 (40.0) | 0.869 |
| Diabetes mellitus, n (%) (n = 223) | 20 (12.7) | 4 (6.2) | 0.235 |
| Rhinosinusitis, n (%) | 12 (7.5) | 8 (12.3) | 0.381 |
| Isolation of Pseudomonas aeruginosa, n (%) | 15 (9.5) | 8 (12.3) | 0.700 |
| Tuberculosis, n (%) (n = 223) | 71 (44.7) | 25 (39.1) | 0.540 |
| Pre-bronchodilator spirometry results (n = 216) |                 |                 |       |
| FVC (L)         | 2.5 (1.9–3.1)    | 2.2 (1.7–2.7)    | 0.006 |
| FVC (%-predicted) | 69.7 (59.0–79.2) | 62.3 (50.3–75.8) | 0.003 |
| FEV₁ (L)        | 1.4 (1.1–1.8)    | 1.1 (0.9–1.7)    | 0.002 |
| FEV₁ (%-predicted) | 55.6 (44.8–85.4) | 46.9 (35.1–59.6) | 0.002 |
| FEV₁/FVC (%)    | 60.3 (51.9–65.7) | 57.4 (47.2–65.5) | 0.239 |
| Medication      |                 |                 |       |
| Inhaler (n = 222) |             |                 |       |
| LABA or LAMA only, n (%) | 19 (12.0) | 4 (6.2) | 0.300 |
| ICS/LABA, n (%)  | 13 (8.2)        | 7 (10.9)         | 0.704 |
| LABA/LAMA, n (%) | 73 (46.2)       | 32 (50.0)        | 0.715 |
| ICS/LABA/LAMA, n (%) | 26 (16.5) | 13 (20.3) | 0.625 |
| Oral drug (n = 223) |             |                 |       |
| Statin, n (%)   | 12 (7.5)        | 4 (6.2)          | 0.958 |
| ACE inhibitor, n (%) | 1 (0.6) | 0 (0.0) | 1.000 |
| Proton pump inhibitor, n (%) | 13 (8.2) | 6 (9.4) | 0.980 |

Data are expressed as medians (interquartile ranges) for continuous variables and numbers (percentages) for categorical variables.

*Decreased QoL was defined as the lowest quartile of the total BHQ score (<57). †Six patients switched from one inhaler to the other.

COPD, chronic obstructive pulmonary disease; QoL, quality of life; BMI, body mass index; mMRC, modified Medical Research Council; FVC, forced vital capacity; FEV₁, forced expiratory volume in 1 second; BSI, bronchiectasis severity index; PHQ-9, patient health questionnaire 9; FFS, fatigue severity scale; ICS, inhaled corticosteroid; LABA, long-acting β₂ agonist; LAMA, long-acting muscarine antagonist; ACE, angiotensin-converting enzyme.
11–23), \( p < 0.001 \), PHQ-9 [median 11 (IQR, 7–17) vs. median 2 (IQR, 1–4), \( p < 0.001 \)], and FFS [median 37 (IQR, 28–51) vs. median 15 (IQR, 11–23), \( p < 0.001 \)] were significantly higher in patients with decreased QoL than those without decreased QoL.

**Factors Associated With Decreased QoL in Bronchiectasis With COPD**

In univariable analyses, BMI [per each 1-kg/m\(^2\) decrease; unadjusted odds ratio (OR) = 1.12, 95% confidence interval (CI) = 1.03–1.23], mMRC ≥ 2 (unadjusted OR = 8.06, 95% CI = 4.13–16.25), PHQ-9 (per each 1-score increase, unadjusted OR = 1.40, 95% CI = 1.28–1.55), FFS (per each 1-score increase; unadjusted OR = 1.11, 95% CI = 1.08–1.14), FEV\(_1\)% predicted (per each 10% decrease; unadjusted OR = 1.33, 95% CI = 1.08–1.65), and modified Reiff score (per each 1-score increase; unadjusted OR = 1.08, 95% CI = 1.00–1.16) were significantly associated with decreased QoL. However, in multivariable analysis, mMRC ≥ 2 (adjusted OR = 3.21, 95% CI = 1.21–8.60), PHQ-9 (per each 1-score increase; adjusted OR = 1.28, 95% CI = 1.16–1.44), and FFS (per each 1-score increase; adjusted OR = 1.05, 95% CI = 1.01–1.09) were significantly associated with decreased QoL (Table 3).

**DISCUSSION**

In this prospective observational study, we compared QoL scores in bronchiectasis patients in Korea according to COPD presence. We found that ~38% of patients with bronchiectasis have COPD, and these patients had lower QoL as measured by the BHQ than do patients without COPD. We additionally found that dyspnea estimated by mMRC (≥ 2), depression by PHQ-9, and fatigue by FSS were significant factors associated with decreased QoL among bronchiectasis patients with COPD.

The coexistence of COPD and bronchiectasis in Western countries is < 20% (1, 2, 4). Although COPD prevalence according to India's bronchiectasis registry was higher than the prevalences in Western countries, it was still only around 20% (3). In comparison, the COPD prevalence in the KMBARC registry was higher than expected, but it is not clear why. There are some possible explanations for the phenomenon. In this study, COPD was defined as physician-diagnosed COPD. Thus, the definition of COPD was not as strict as that in the previous Taiwan study that included smoking history as well as spirometric results (30). Another possibility is that bronchiectasis with obstructive ventilatory impairment might have been regarded as having COPD. Bronchiectasis itself can cause obstructive ventilatory impairment (31). The high rate of COPD can be also attributable to the relatively high prevalence of asthma and TB in this cohort (14). The current Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations indicate asthma or TB as a risk factor of COPD (32). We carefully suggest that asthmatic patients with fixed airflow obstruction and prior TB patients with airflow obstruction might have been regarded as COPD by attending physicians.

| TABLE 3 | Factors associated with decreased quality of life in patients with coexisting COPD and bronchiectasis. |
|---|---|
| Factors (n = 203) | Decreased quality of life (total BHQ score < 57) |
| | Univariable analysis | Multivariable analysis |
| | Unadjusted OR (95% CI) | p-value | Adjusted OR (95% CI) | p-value |
| Age, per each 1-year increase | 1.00 (0.97–1.03) | 0.924 | 1.01 (0.97–1.06) | 0.554 |
| Sex | | | | |
| Female | Ref. | | | |
| Male | 0.86 (0.46–1.57) | 0.589 | 0.79 (0.21–2.87) | 0.716 |
| Smoking history | | | | |
| Never-smoker | Ref. | | | |
| Current or ex-smoker | 0.88 (0.48–1.62) | 0.690 | 0.90 (0.25–3.24) | 0.866 |
| BMI (kg/m\(^2\)), per each 1-kg/m\(^2\) decrease | 1.12 (1.03–1.23) | 0.013 | 1.03 (0.91–1.17) | 0.613 |
| Symptoms | | | | |
| mMRC < 2 | Ref. | | | |
| mMRC ≥ 2 | 8.06 (4.13–16.25) | <0.001 | 3.21 (1.21–8.60) | 0.019 |
| PHQ-9, per each 1-score increase | 1.40 (1.28–1.55) | <0.001 | 1.28 (1.16–1.44) | <0.001 |
| FSS, per each 1-score increase | 1.11 (1.08–1.14) | <0.001 | 1.05 (1.01–1.09) | 0.020 |
| Acute exacerbation | | | | |
| No | Ref. | | | |
| Yes | 1.53 (0.82–2.95) | 0.190 | 1.55 (0.58–4.34) | 0.389 |
| FEV\(_1\)% predicted, per each 10-percent decrease | 1.33 (1.08–1.65) | 0.008 | 0.94 (0.68–1.32) | 0.730 |
| Modified Reiff score, per each 1-score increase | 1.08 (1.00–1.16) | 0.046 | 1.06 (0.93–1.20) | 0.373 |

The ORs, CIs, and p-values were calculated from logistic regression analysis. In the multivariable model, all factors were included for adjustment.

COPD, chronic obstructive pulmonary disease; BHQ, bronchiectasis health questionnaire; BMI, body mass index; mMRC, modified Medical Research Council; PHQ-9, Patient Health Questionnaire 9; FSS, Fatigue Severity Score; FEV\(_1\), forced expiratory volume in 1 second; OR, odds ratio; CI, confidence interval.
physicians. Thus, the burden of COPD-related risk factors other than smoking was relatively high in our cohort, which might have led to a high rate of never-smokers in bronchiectasis patients with COPD. Although there are prevalence differences between our study and previous studies, these results suggest that at least one-fifth of bronchiectasis patients have COPD, and appropriate diagnosis and treatment are important for proper management.

It is well-recognized that bronchiectasis patients have lower QoL than patients without bronchiectasis (33), especially patients with exacerbations and respiratory symptoms (34). However, the QoL of bronchiectasis patients with COPD has rarely been evaluated. One European study analyzed bronchiectasis patients’ QoL according to etiology, and patients with COPD-related bronchiectasis were shown to have lower QoL compared with patients with bronchiectasis caused by other etiologies (35). However, because that study evaluated QoL according to etiology, COPD patients whose COPD was not considered to be the cause of bronchiectasis were not included in the COPD group. By viewing COPD as comorbidity and not taking an etiology-based approach, our study showed that COPD significantly affected the QoL of patients with bronchiectasis. However, it should be mentioned that the minimal clinically important difference in the BHQ scores is not known. As a result, although the median difference of 1.7 units was statistically different in bronchiectasis patients by the presence or absence of COPD, this difference may not be clinically significant. Future studies are needed.

Among factors associated with QoL in bronchiectasis patients with COPD, dyspnea measured by mMRC had the most significant association with decreased QoL. This suggests that poorly controlled dyspnea can lead to poor QoL in bronchiectasis patients with COPD. Consistent with our results, a previous study using a COPD cohort showed that COPD patients with bronchiectasis have a high degree of dyspnea, which affected patients’ QoL as measured by SGRQ score (12). Other important findings of our study are that depression and fatigue measured by PHQ-9 and FFS, respectively, affected QoL in bronchiectasis patients with COPD. Fatigue and depression are frequent in patients with COPD as well as those with bronchiectasis and have significant impacts on QoL in these patients (36–38). Accordingly, it can be postulated that these two conditions can affect the QoL in patients with bronchiectasis and COPD overlap. Regarding these conditions affecting the QoL in bronchiectasis patients with COPD, previous study findings suggest that these symptoms can be interactively connected, and one symptom may affect others. For example, a patient who complains of dyspnea may have unrecognized fatigue or depression as well. Thus, a strategy focusing on one component might not be as effective as a comprehensive approach to managing all these factors (e.g., bronchodilator use, pulmonary rehabilitation, as well as anti-depression treatment). Future studies are needed to optimize the assessment and treatment strategies to improve QoL in bronchiectasis patients with COPD.

There are some limitations to our study. First, this study was performed in Korean bronchiectasis patients. Thus, to generalize our findings, further studies using other bronchiectasis cohorts are needed. Second, because our study design was cross-sectional, we could not evaluate the association between COPD and longitudinal changes in QoL in bronchiectasis patients. Thus, future studies are needed. Third, although we suggested some potential reasons (TB, asthma, etc.) to explain the high proportion of never-smokers in bronchiectasis patients with COPD, the role of other important risk factors (e.g., biomass exposure) on this issue could not be evaluated due to the lack of data in KMBARC.

CONCLUSIONS

COPD was a significant factor associated with decreased QoL in patients with bronchiectasis. Dyspnea, depression, and fatigue were associated with reduced QoL in bronchiectasis patients with COPD. In managing patients with bronchiectasis, appropriate diagnosis and treatment of COPD might help improve QoL.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The study protocol was approved by the institutional review board of each institution that participated in the KMBARC, including Hallym University Chuncheon Sacred Heart Hospital (IRB number: 2018-07-006). All participants provided written informed consent.

AUTHOR CONTRIBUTIONS

HL and YK are guarantors of the manuscript. SK, HL, and YK designed the study and wrote the initial draft of the manuscript. SK performed data analysis. All authors were involved at all stages of the critical revision of the manuscript, read and approved the final manuscript, and meet the criteria for authorship as recommended by the International Committee of Medical Journal Editors.

FUNDING

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science, Information and Communications Technologies (MSIT) (NRF-2020R1F1A1070468 and NRF-2021M3E5D1A01015176). This work was also supported by the Korea Medical Device Development Fund grant funded by the Korea government (the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health & Welfare, the Ministry of Food and Drug Safety) (Project Number: 1711138447, KMDF_PR_20200901_0214).
ACKNOWLEDGMENTS

The authors thank all members of the Korean Multicentre Bronchiectasis Audit and Research Collaboration (KMBARC) registry: Y-MO, HL, Hayoung Choi, Yun Su Sim, Woo Jin Kim, Kwang Ha Yoo, SL, TK, Rumhee Yang, IJ, Soo-Jung Um, Deog Kyeom Kim, Ji-Hyun Lee, Byoung Soo Kwon, Young-Jae Cho, Chang-Hoon Lee, Chin Kook Rhee, Sang Haak Lee, Ju-Ok Na, An-Soo Jang, Ji Ye Jung, Ji-Ho Lee, Sang Ha Kim, CK, YK, CL, Hyun Kuk Kim, Hye Yun Park, Jae Seung Lee, Sei Won Lee, Seung Won Ra, Sung-Yoon Kang, Yee Hyung Kim, Yong Bum Park, Sooim Sin, So-Young Park, Junghyun Kim, Young-Soon Yoon, Yun Jeong Jeong, Jung-Kyu Lee, Ki Uk Kim, Hyun-Kyung Lee, Eun Kyung Kim, Se Hee Lee, Jae Sung Choi, Hyung Koo Kang, Yong-Soo Kwon, Jae Ha Lee, Eun Hye Lee, and Ji Soo Choi.

REFERENCES

1. Aksamit TR, O’Donnell AE, Barker A, Olivier KN, Winthrop KL, Daniels MLA, et al. Adult patients with bronchiectasis: a first look at the US bronchiectasis research registry. Chest. (2017) 151:982–92. doi: 10.1016/j.chest.2016.10.055
2. Araújo D, Steinberg M, Aliberti S, Goeminne PC, Hill AT, Fardon TC, et al. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur Respir J. (2018) 51:1953. doi: 10.1183/13993003.01953-2017
3. Dhari R, Singh S, Talwar D, Mohan M, Tripathi SK, Swarnarak R, et al. Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. Lancet Glob Health. (2019) 7:e1269-79. doi: 10.1016/S2214-109X(19)30327-4
4. Visser SK, Bye RTP, Fox Gl, Burr LD, Chang AB, Holmes-Liew CL, et al. Australian adults with bronchiectasis: the first report from the Australian Bronchiectasis Registry. Respir Med. (2019) 155:97–103. doi: 10.1016/j.rmed.2019.07.016
5. Choi H, Yang B, Nam H, Kyoung DS, Sim YS, Park HY, et al. Population-based prevalence of bronchiectasis and associated comorbidities in South Korea. Eur Respir J. (2019) 54:194. doi: 10.1183/13993003.00194-2019
6. Martinez-García MA, Miravilles M. Bronchiectasis in COPD patients: more than a comorbidity? Int J Chron Obstruct Pulmon Dis. (2017) 12:1401. doi: 10.2147/COPD.S12961
7. Ni Y, Shi G, Yu Y, Hao J, Chen T, Song H. Clinical characteristics of patients with chronic obstructive pulmonary disease with comorbid bronchiectasis: a system review and meta-analysis. Int J Chron Obstruct Pulmon Dis. (2015) 10:1465–75. doi: 10.2147/COPD.S83910
8. Gatheral T, Kumar N, Sansom B, Lai D, Nair A, Vlahos I, et al. COPD-related bronchiectasis; independent impact on disease course and outcomes. COPD. (2014) 11:605–14. doi: 10.3109/15412255.2014.921714
9. Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, Wilks M, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. (2004) 170:400–7. doi: 10.1164/rccm.200305-648OC
10. Mao B, Lu HW Li MH, Fan LC, Yang JW, Xiao XY, et al. The existence of bronchiectasis predicts worse prognosis in patients with COPD. Sci Rep. (2015) 5:10961. doi: 10.1038/srep10961
11. Ekici A, Bulcun E, Karakoc T, Senturk E, Ekici M. Factors associated with quality of life in subjects with stable COPD. Respir Care. (2015) 60:1585–91. doi: 10.4187/respcare.03904
12. Sahin H, Naz I, Susam S, Erbaycu AE, Olcay S. The effect of the presence and severity of bronchiectasis on the respiratory functions, exercise capacity, dyspnea perception, and quality of life in patients with chronic obstructive pulmonary disease. Ann Thorac Med. (2020) 15:26–32. doi: 10.4103/atom.AM_198_19
13. Lee H, Choi H, Sim YS, Park S, Kim WJ, Yoo KH, et al. KMBARC registry: protocol for a multicentre observational cohort study on non-cystic fibrosis bronchiectasis in Korea. BMJ Open. (2020) 10:e034090. doi: 10.1136/bmjopen-2019-034090
14. Lee H, Choi H, Chalmers JD, Dhar R, Nguyen TQ, Visser SK, et al. Characteristics of bronchiectasis in Korea: first data from the Korean Multicentre Bronchiectasis Audit and Research Collaboration registry and comparison with other international registries. Respirology. (2021) 26:619–21. doi: 10.1111/resp.14059
15. Kim HK, Lee H, Kim S-H, Choi H, Lee IH, Lee JS, et al. Validation of the Korean version of the bronchiectasis health questionnaire. Tuberc Respir Dis. (2020) 83:228–33. doi: 10.4046/trd.2020.0025
16. Hill AT, Sullivan AL, Chalmers JD, De Soeya Z, Elborn JS, Floto RA, et al. British Thoracic Society Guideline for bronchiectasis in adults. Thorax. (2019) 74:1–69. doi: 10.1136/thoraxjnl-2018-212463
17. Spinou A, Siegert RJ, Guan WJ, Patel AS, Gosker HR, Lee KK, et al. The development and validation of the bronchiectasis health questionnaire. Eur Respir J. (2017) 49:1532. doi: 10.1183/13993003.01532-2016
18. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. (1988) 93:580–6. doi: 10.1378/chest.93.3.580
19. Murray M, Pentland I, Turnbull K, MacQuarrie S, Hilt A, Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis. Eur Respir J. (2009) 34:361–4. doi: 10.1183/09031936.00163208
20. Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. (2017) 49:51. doi: 10.1183/13993003.00051-2017
21. Chalmers JD, Goeminne P, Aliberti S, McDonald MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. (2014) 189:576–85. doi: 10.1164/rccm.201310-1575OC
22. Martinez-García M, de Gracia J, Vendrell Relat M, Girón RM, Maíz Carro L, de la Rosa Carrillo D, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J. (2014) 43:1357–67. doi: 10.1183/09031936.00026313
23. Kronke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. (2001) 16:606–13. doi: 10.1046/j.1525-1497.2001.01609x.x
24. Park S-J, Choi H-R, Choi J-H, Kim K-W, Hong J-P. Reliability and validity of the Korean version of the Patient Health Questionnaire-9 (PHQ-9). Anxiety Mood. (2010) 6:119–24.
25. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. (1989) 46:1121–3. doi: 10.1001/archneur.1989.005302040115022
26. Lee JH, Jeong HS, Lim SM, Cho HR, Ma J-Y, Ko E, et al. Reliability and validity of the fatigue severity scale among University Student in South Korea. Korean J Biol Psychiatry. (2013) 20:6–11. Available online at: http://journal.biopsychoiatry.or.kr/aspi/journal_fulltxt.asp?no=0092013002&m=0 (accessed July 29, 2021).
27. Mandal P, Patel D, Hill A. A simplified CT scoring system in non-cystic fibrosis bronchiectasis. Eur Respir Soc. (2013) 42:2241. Available online at: https://erj.ersjournals.com/content/42/Suppl_57/P241.short (accessed July 29, 2021).
28. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. (2005) 26:319–38. doi: 10.1183/09031936.05.0034805
29. Choi JK, Paek D, Lee JO. Normal predictive values of spirometry in Korean population. Tuberc Respir Dis. (2005) 58:230–42. doi: 10.4046/trd.2005.58.3.230
30. Huang H-Y, Chung F-T, Lo C-Y, Lin H-C, Huang Y-T, Yeh C-H, et al. Etiology and characteristics of patients with bronchiectasis in Taiwan: a cohort study from 2002 to 2016. *BMC Pulm Med.* (2020) 20:45. doi: 10.1186/s12890-020-1080-7

31. Yang B, Jang HJ, Chung SI, Yoo SJ, Kim T, Kim SH, et al. Factors associated with bronchiectasis in Korea: a national database study. *Ann Transl Med.* (2020) 8:1350. doi: 10.21037/atm-20-4873

32. GOLD. *Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease.* (2021). Available online at: http://www.goldcopd.org (accessed July 29, 2021).

33. Yang B, Choi H, Lim JH, Park HY, Kang D, Cho J, et al. The disease burden of bronchiectasis in comparison with chronic obstructive pulmonary disease: a national database study in Korea. *Ann Transl Med.* (2019) 7:770. doi: 10.21037/atm.2019.11.55

34. Gao YH, Abo Leyah H, Finch S, Lonergan M, Aliberti S, De Soyza A, et al. Relationship between symptoms, exacerbations, and treatment response in bronchiectasis. *Am J Respir Crit Care Med.* (2020) 201:1499–507. doi: 10.1164/rccm.201910-1972OC

35. Terpstra LC, Biesenbeek S, Altenburg J, Boersma WG. Aetiology and disease severity are among the determinants of quality of life in bronchiectasis. *Clin Respir J.* (2019) 13:521–9. doi: 10.1111/crj.13054

36. Kouijzer M, Brusse-Keizer M, Bode C. COPD-related fatigue: impact on daily life and treatment opportunities from the patient’s perspective. *Respir Med.* (2018) 141:47–51. doi: 10.1016/j.resmed.2018.06.011

37. Lee H, Jhun BW, Cho J, Yoo KH, Lee JH, Kim DK, et al. Different impacts of respiratory symptoms and comorbidities on COPD-specific health-related quality of life by COPD severity. *Int J Chron Obstruct Pulmon Dis.* (2017) 12:3301–10. doi: 10.2147/COPD.S145910

38. Olveira C, Olveira G, Gaspar I, Dorado A, Cruz I, Soriguer F, et al. Depression and anxiety symptoms in bronchiectasis: associations with health-related quality of life. *Qual Life Res.* (2013) 22:597–605. doi: 10.1007/s11136-012-0188-5

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.